Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiopulmonary Resuscitation III: AED Use

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Special Report on the NHLBI Initiative to Study Cellular and Molecular Mechanisms of Arterial Stiffness and Its Association With Hypertension.

Circulation research·2017

Same author

A Physical Heart Failure Simulation System Utilizing the Total Artificial Heart and Modified Donovan Mock Circulation.

Artificial organs·2016

Same author

Remodeling an infarcted heart: novel hybrid treatment with transmyocardial revascularization and stem cell therapy.

SpringerPlus·2016

Same author

Functional aortic stiffness: role of CD4(+) T lymphocytes.

Frontiers in physiology·2015

Same author

Reliability of the Thoratec HeartMate II flow measurements and alarms in the presence of reduced or non-existent flow.

Perfusion·2015

Same author

Effect of lysyl oxidase inhibition on angiotensin II-induced arterial hypertension, remodeling, and stiffness.

PloS one·2015

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

CardioWest temporary total artificial heart.

Anthony Platis¹, Douglas F Larson

¹Circulatory Sciences Graduate Perfusion Program, College of Medicine, The University of Arizona, Tucson, AZ 85724, USA.

|November 18, 2009

Summary

The CardioWest temporary total artificial heart (TAH-t) significantly improves survival rates for heart failure patients awaiting transplant. This device offers a promising future for end-stage heart failure treatment.

Area of Science:

Cardiovascular Medicine
Biomedical Engineering

Background:

The CardioWest temporary total artificial heart (TAH-t) is a ventricular assist device designed to replace both native heart ventricles.
It offers distinct advantages over traditional ventricular assist devices (VADs) for specific patient populations.
Over 715 patients have received the TAH-t across 30 international centers since 1993 as a bridge-to-transplant (BTT).

Purpose of the Study:

To review the current literature and highlight the historical development of the CardioWest TAH-t.
To evaluate the efficacy and survival benefits of the TAH-t in patients with end-stage heart failure.

Main Methods:

The review synthesizes data from multiple institutional centers worldwide.
Focuses on the unique mechanical flow dynamics and design of the TAH-t.

More Related Videos

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Compares outcomes of patients receiving the TAH-t (protocol group) with control groups.

Main Results:

Survival to transplant was 79% in the TAH-t group versus 46% in the control group (P < 0.001).
One-year survival was 70% for TAH-t recipients compared to 31% for controls (P < 0.001).
Post-transplant survival rates at one and five years were significantly higher in the TAH-t group (86% and 64%) versus the control group (69% and 34%).

Conclusions:

The CardioWest TAH-t demonstrates superior survival outcomes for end-stage heart failure patients.
Its advanced design facilitates adequate organ perfusion and patient recovery.
Represents a significant advancement in medical engineering for treating heart failure.